Kornimate/medical-research-clean huggingface dataset:
massively parallel sequencing to identify microbiological organisms in bronchoalveolar lavage fluid

Conditions: Pulmonary Infection

Summary: patients who are post hematopoietic stem cell transplantation who require a bronchoalveolar lavage (bal) for standard clinical car will have extra fluid collected and sent for massively parallel sequencing to see if it is as sensitive for detecting a microbial pulmonary infection compared to standard cultures.

5.1 subjects will undergo bronchoscopy and bal based on clinical indications. techniques and equipment will be per current clinical practice at westchester medical center (wmc). the bronchoscope is usually introduced either via an artificial airway (endotracheal tube or laryngeal mask airway). the lavage is performed with sterile normal saline. the site of performing the lavage is selected based on radiologic or clinical data and on the appearance of the airways during the bronchoscopy. the typical volume of the lavage is 3 aliquots of 1 ml/kg each, with a max of 20 ml per aliquot. 5.2 when 10 ml or more of bal fluid is received by the wmc laboratory, the bal fluid will be divided by the wmc laboratory for all physician ordered clinical laboratory tests and for massively parallel sequencing research tests. this will ensure that sufficient bal material is available for all clinical tests. 5.3 the bal fluid for research will be held by the wmc laboratory and picked up by research personnel for processing at new york medical college genomics core facility. 5.4 the research portion will be further divided for isolation of viral, bacterial, and fungal nucleic acid isolation. a control sample of fluid used for the bal will be prepared in parallel. bacterial/fungal dna and viral dna and rna will be isolated. whole genome sequencing libraries will be generated and sequenced in batches on the illumina miseq. fastq files will be demultiplexed and then aligned to microbial genomes using phylosift.11 dna sequences present in both the patient and control samples will be discarded as contaminant. the preponderant organism(s) identified will be matched to the results of the culture based techniques used to verify the culture independent results.

Eligibility criteria:
inclusion criteria * patient age \< 30 years * recipient of an autologous or allogeneic stem cell transplant in the previous 365 days * requires a bronchoalveolar lavage for clinical indications * signed consent exclusion criteria * lack of signed informed consent
"escape" phenomenon of the antihypertensive therapy efficacy

Conditions: Arterial Hypertension

Summary: a little attention is paid to the aht efficacy escaping problem, which can be explained by the aht correction simplicity and rapid achievement of the target bp level. nevertheless, modern statistic data on the effective ah treatment described above let us assume that aht correction is either totally absent or is untimely in case of the "escape" phenomenon development. this could be one of the main reasons for the high prevalence of ineffective ah treatment. the aim of this study is to determine aht efficacy "escape" phenomenon timeline and its predictors in hypertensive patients.


Eligibility criteria:
inclusion criteria: * arterial hypertension (ah) grade 1-3, stage i-ii * high compliance during the follow-up period (≥ 85%) * initially achieved target office bp levels while taking 2-3-component aht exclusion criteria: * secondary ah * resistant ah, * ah iii stage, * pap- therapy, * type 2 diabetes mellitus, * pregnancy * history of low adherence to treatment
intracochlear potentials: volta study

Conditions: Hearing Loss

Summary: collection of normative voltage tomography data during and/or immediately after electrode insertion into the cochlea using surgical assistant (sa16) research software and postoperatively at activation, three and twelve months post-activation with cs19 research software in adults who are receiving a cochlear nucleus ci512, ci422, ci522 or ci532 cochlear implant.

the clinical investigation will gather impedance and transimpedance (voltage tomography) data intraoperatively and post-operatively which can be used to characterize the electrical properties of the living cochlea. the surgical assistant research tool (sa16) research software is a software tool developed by cochlear limited. the use of the sa16 research software in the current clinical investigation is intended to support cochlear's research into the development of implant telemetry based surgical tools. the sa16 research software is designed to perform a series of predefined measurements with minimal intervention both during and immediately following electrode insertion using telemetry from the implant via the sound processor to the computer. these measurements include real time continuous measurements, intended for use during the electrode insertion portion of the surgical procedure, and baseline measurements following the completion of electrode insertion. the sa16 research software will be used in the current clinical investigation in adults who meet current indications for cochlear implantation in australia. the sa16 research software is not for use with patients who are receiving an implant that directly contacts neural tissue, such as auditory brainstem implants (abi). cs19 (1.6.2) software will be used to collect voltage tomography measurements post-implantation.

Eligibility criteria:
inclusion criteria: 1. meet current cochlear implant indications at the implanting centre for a cochlear nucleus ci512, ci422, ci522 or ci532 cochlear implant 2. aged 18 years and older at the time of implantation. exclusion criteria: 1. recipient of a nucleus 24 abi device 2. medical or psychological conditions that contraindicate undergoing general anaesthesia or surgery. 3. ossification, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by medical examination. 4. unwillingness or inability of the candidate to comply with all investigational requirements.

Keywords: voltage tomography
the validity of the thai version of the confusion assessment method

Conditions: Delirium

Summary: the purpose of this study is to determine the validity and reliability of the thai version of the confusion assessment method for the intensive care (cam-icu) in the elderly and the prevalence of delirium in elderly.

the incidence of delirium in intensive care unit varied between 20 and 80% depending on many factors such as types of study, diagnostic tools, severity of patients.the occurrence of delirium is common in elderly patients. however, the prevalence of delirium in the intensive care has not been reported in thailand. there is no common tool used for detecting delirium in thai icu. currently, cam-icu has been developed for nonpsychiatric physician and other health care professionals to detect delirium. the sensitivity and specificity of cam-icu was 91-93% and 89-100% respectively. in addition, it has been translated to many version to diagnose deliriums for all over the world. in thailand, there is no common tool used for detecting delirium in icu. the use of cam-icu may be useful in thai icu settings.

Eligibility criteria:
inclusion criteria: * age ≥ 55 years old exclusion criteria: * severe visual or auditory impairment * comatose or moribund patients * unable to communicate with thai language

Keywords: delirium of mixed origin subacute delirium mental disorders, organic organic brain syndrome, nonpsychotic organic mental disorders organic mental disorders, psychotic psychoses, traumatic cognition disorder confusion state disorientation
the effect of combination of dapagliflozin and sildenafil in treatment of heart failure patients with secondary pulmonary hypertension

Conditions: Heart Failure NYHA Class II

Summary: this study aims to determine the efficacy of sildenafil (improve pah) as an add-on therapy to dapagliflozin in the treatment of heart failure patients with secondary pulmonary arterial hypertension and compare the result with monotherapy dapagliflozin


Eligibility criteria:
inclusion criteria: patients with established heart failure with secondary pulmonary hypertension seen by a primary care provider to diagnose a heart disease, the patient's symptoms which may experience: * dizziness or fainting * heart palpitations, which may feel like your heart fluttering or skipping beats * shortness of breath exclusion criteria: * patients with a history of severe allergic reactions or hypersensitivity to sildenafil, dapagliflozin, or related medications. * individuals with contraindications to the use of sildenafil or dapagliflozin. * patients with pulmonary arterial hypertension (pah) due to conditions other than heart failure (e.g., idiopathic pah). * severe hepatic impairment * aged less than 18 years. * valvular heart disease . * patients with a known or suspected history of non-compliance with medical treatment or inability to adhere to study procedures. * life expectancy of less than 6 months . * pregnant or breastfeeding women
a study of vac85135, a neoantigen vaccine regimen, concurrently administered with ipilimumab for the treatment of myeloproliferative neoplasms

Conditions: Myeloproliferative Neoplasms

Summary: the purpose of this study is to evaluate the safety of vac85135 administered with ipilimumab for the treatment of myeloproliferative neoplasms (mpns).


Eligibility criteria:
inclusion criteria: * be positive for a calr (calreticulin) mutation: type 1 or type 2; type 1-like, or type 2-like may be considered with sponsor approval; or positive for the jak2v617f (janus kinase 2 with valine 617 to phenylalanine mutation) mutation with hla-a02:01 (human leukocyte antigens) per medical history or local testing * have an eastern cooperative oncology group (ecog) performance status grade of 0 or 1 or 2 * have the following hematologic laboratory values: leukocytes greater than or equal to (\>=) 1.5\*10\^9 per liter, neutrophils \>=1.0\*10\^9 per liter, platelets \>=20\*10\^9 per liter, hemoglobin greater than (\>) 7 gram per deciliter (g/dl) * have the following chemistry laboratory values: alanine aminotransferase (alt): less than or equal to (\ =40 milliliter per minute (ml/min) * a female participant of childbearing potential must agree to all the following during the study and for 6 months after the last dose of study treatment: use a barrier method of contraception, use a highly effective preferably user-independent method of contraception, not to donate eggs (ova, oocytes) or freeze for future use for the purposes of assisted reproduction, not plan to become pregnant, not to breast-feed * a male participant must agree to all the following during the study and for 90 days after the last dose of study treatment: wear a condom when engaging in any activity that allows for passage of ejaculate to another person, not to father a child, not to donate sperm or freeze for future use for the purpose of reproduction exclusion criteria: * history of any significant medical condition per investigators judgment (example: severe asthma/chronic obstructive pulmonary disease (copd), poorly regulated heart condition, insulin dependent diabetes mellitus) * serious known clinically relevant allergies or earlier anaphylactic reactions * currently pregnant or breastfeeding * prior treatment with any janus kinase 1/2 (jak1/2) inhibitor * known sensitivity or contraindications to the use of ipilimumab per local prescribing information
impact of acceptance and commitment therapy on early stage breast cancer

Conditions: Breast Neoplasms; Survivorship; Stress

Summary: the purpose of this randomized controlled trial is to evaluate the effectiveness of an empirically supported psychosocial treatment, acceptance and commitment therapy, in facilitating improved quality of life, benefit-finding, and cortisol rhythm in breast cancer patients in an outpatient clinical oncology setting.

previous research indicates that breast cancer patients may demonstrate disrupted diurnal cortisol rhythms compared to healthy individuals, and that these disrupted rhythms may be related to recurrence and earlier mortality in some patients. interestingly, improvements in cortisol regulation in previous intervention studies for cancer patients have not necessarily been related to decreased distress. rather, improvements in post-traumatic growth, benefit-finding, and meaningfulness have also accounted for improved neuroendocrine and immunological changes. traditional breast cancer groups, however, may not adequately address these areas because existing interventions often target the reduction of distress as the primary vehicle to improve psychosocial, quality of life, and biophysical outcomes. acceptance and commitment therapy (act) is an empirically-supported, mindfulness-based psychological treatment that has been shown to enhance meaningful behavior change thorough increasing emotional acceptance of difficult psychological experiences such as distress, without the goal of changing or eliminating them. the current study seeks to determine the preliminary effect of an 8-week act group in increasing positive life changes and corresponding increase in salivary cortisol slope in 40 distressed breast cancer patients, who will be randomly assigned to act or a wait list control group. the hypotheses for the present study include: * patients receiving act will demonstrate improvements in quality of life (qol), benefit-finding (bf), and health behavior compared to control group participants * act participants will demonstrate improvements in mean cortisol levels and cortisol reactivity compared to control group participants * these changes will be the result of increased mindful acceptance of cancer-related distress and meaningful behavior changes, rather than a reduction in distress.

Eligibility criteria:
inclusion criteria: * diagnosis of stage i-iii breast cancer * prescreen distress score above defined cutoff * agreement not to seek other breast cancer support services until study completion exclusion criteria: * previous cancer * prior psychiatric treatment for serious mental health disorder (e.g., hospitalization or formal diagnosis of psychosis, major depressive episode, borderline mental retardation, suicidality, or current substance dependence) * current use of medications known to interfere with cortisol levels (e.g., dexamethasone) * major concurrent medical disease
growth pattern and characteristics of cardiac pediatric patients

Conditions: Growth Disorders

Summary: congenital heart disease (chd) is the most common congenital anomaly in the body, affecting about 8 per 1000children. cardiovascular disorders are the most debilitating and one of causes of organic growth disorders in children.malnutrition is a constant phenomenon among children with chd. the degree and type of malnutrition may be related to characteristics of the chd, including presence of cyanosis, congestive heart failure (chf), or pulmonary hypertension (phtn).

at birth, the weight and length of children with chd are close to normal and apgar scores are generally high. cyanotic patients are affected in growth, depending on the severity of tissue hypoxemia and on the degree of physiological variation. mostly acute malnutrition occurs in a cyanotic heart disease but chronic malnutrition occurs in cyanotic lesions. the severity of malnutrition variety from mild under nutrition to failure to thrive. impairing growth and increasing post-operative morbidity and mortality. early rapid growth retardation detection in early age and improved nutritional status have the potential to reduce cardiac impact on growth and feeding. insure appropriate nutrition in those patients by the two main methods (enteral and parenteral) help in better outcome

Eligibility criteria:
inclusion criteria: * age: 0-4 years old * male and female, * diagnosed as cardiac diseased children exclusion criteria: * children more than 4 years old * not genetic disorder as down syndrome this is a descriptive study.
safety and effectiveness evaluation of the multi-electrode radiofrequency balloon catheter for the treatment of symptomatic paroxysmal atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the primary objective of this clinical investigation is to demonstrate safety and effectiveness of the multi-electrode rf balloon catheter for the treatment of drug refractory symptomatic paroxysmal atrial fibrillation.

the stellar study is a pivotal, prospective, multicenter, single-arm, clinical evaluation of the multi-electrode rf balloon catheter. the study will evaluate the safety and effectiveness of the multi-electrode rf balloon catheter used for ablation in patients with paroxysmal atrial fibrillation (paf).

Eligibility criteria:
key inclusion criteria: * diagnosed with symptomatic paroxysmal atrial fibrillation. 1. at least two symptomatic af episodes within last six months from enrollment. 2. at least one ectrocardiographically documented af episode within twelve (12) months prior to enrollment. * failed at least one class i or class iii antiarrhythmic drug. * age 18 -75 years. key exclusion criteria: * af secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. * previous surgical or catheter ablation for af. * previously diagnosed with persistent or long-standing persistent af and/or continuous af \> 7 days. * any percutaneous coronary intervention within the past 2 months. * valve repair or replacement or presence of a prosthetic valve. * any carotid stenting or endarterectomy within the past 6 months. * coronary artery bypass grafting, cardiac surgery, or valvular cardiac surgical procedure within the past 6 months. * documented left atrium (la) thrombus within 1 day prior to the index procedure. * la antero posterior diameter \> 50 mm. * left ventricular ejection fraction (lvef) \< 40%. * contraindication to anticoagulation (e.g., heparin). * myocardial infarction within the past 2 months. * documented thromboembolic event (including transient ischemic attack) within the past 12 months. * uncontrolled heart failure or new york heart association (nyha) function class iii or iv. * awaiting cardiac transplantation or other cardiac surgery within the next 12 months. * presence of implanted pacemaker or implantable cardioverter defibrillator (icd). * women who are pregnant, lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation. * life expectancy or other disease processes likely to limit survival to less than 12 months.

Keywords: interventional radiofrequency ablation paroxysmal atrial fibrillation
safety, tolerability and pharmacokinetics of lnz101 and lnz100 ophthalmic solutions in healthy adult chinese with presbyopia

Conditions: Presbyopia

Summary: phase i clinical study to evaluate the safety, tolerability and pharmacokinetics of lnz101 and lnz100 ophthalmic solutions in chinese healthy adult subjects with presbyopia

a single-center, randomized, double-blind, placebo-controlled, multiple-dose phase i clinical study to evaluate the safety, tolerability and pharmacokinetics of lnz101 and lnz100 ophthalmic solutions in chinese healthy adult subjects with presbyopia

Eligibility criteria:
inclusion criteria 1. be able and willing to provide written informed consent prior to any study procedure being performed. 2. be able to and willing to use investigational products per study requirements and attend all study assessments, including admission to and stay in the cru on required study days. 3. be chinese healthy male or female subjects aged 45-75 years (inclusive) at screening. 4. be diagnosed and documented to have presbyopia by the investigator at the screening visit. exclusion criteria: 1. have known contraindications or sensitivity to the use of any of the investigational products or its components, or any other medications required by the protocol. 2. have any active systemic or ocular disorder that has a potential risk to or impact on subject safety, study process or study results other than refractive disorder. 3. have presence of any abnormality of the lids, ocular surface, or lacrimal duct system that in the investigator's opinion could affect ophthalmic solution absorption in either eye. 4. have prior (within 14 days of the first dose), current or anticipated use of any contact lenses during study participation. 5. be ineligible for this trial in the opinion of the investigator.

Keywords: presbyopia lnz100 lnz101
risk factors,prevention and outcomes for ci-aki in patients undergoing pci (precise)

Conditions: CIN

Summary: a prospective observational study included all patients undergoing percutaneous coronary intervention(pci) in fujian provincial hospital from january 1st 2012 to december 31st 2018. the aim was to determine the incidence,risk factors,prophylactic strategy and outcomes of ci-aki in patients undergoing pci.


Eligibility criteria:
inclusion criteria: * critically ill patients undergoing pci at icu exclusion criteria: * pregnancy lactation end-stage renal disease (egfr \<15 ml/min/1.73 m2) long-term dialysis treatment intravascular administration of contrast medium within the last 7 or 3 days postoperatively
effect of technology-assisted physical therapy for patient with high risk of sarcopenia

Conditions: Sarcopenia

Summary: this research aims to identify whether the effects of video-assisted physical therapy, including home resistance training, is superior to traditional physical therapy, education leaflet for example. this is an interventional research, single-blind, randomized control trail. we recruit high risk of sarcopenia people (low muscle strength and low physical performance) two groups of participants are divided into traditional group and video-assisted group, both group are taught the same resisted exercise by physical therapist.

both group will record his/her baseline activity level with a given pedometer. after one week recording, we started initial evaluation (history taking, physical examination) and intervention. participants are taught thera-band resisted exercise, including large musculature of upper and lower extremities, each exercise are conducted 10-15 times for 3 sets. traditional group will receive an education leaflet and a notebook to record his/ her daily activity and frequency of exercise to record the compliance. video-assisted group will receive a qr code, which contain a website of exercise video on the cloud. after 3 months intervention, participant will come back to our center for final examination.

Eligibility criteria:
inclusion criteria: * age above 65 years old * mmse \> 24 points * walking more than 6 meters independently exclusion criteria: * people who cannot participate for 3 -day exercise for each week

Keywords: sarcopenia